Agreed. The only thing from a laypersons perspective that might be an issue is that one of the key side effects was a potential for bruising (body wide, not just at the injection site), indicating a possible effect on capillary strength or stability. Not sure if it had a more general effect on the vascular system. Considering that the assumed cohort for this medication would generally be elderly, how many would be on blood thinners such as Warfarin? Not a biggie, but just something else for the developers to consider.
Enlighten me please., page-14
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 20.0¢ | $152.8K | 744.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 78174 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 84426 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |